Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Rybelsus (semaglutide) is a brand-name prescription ... If a person has an Original Medicare plan and Part D, they will pay a separate monthly premium for Part D in addition to their Part B ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, ...

The expected out-of-pocket costs for commonly used drugs like Eliquis and Ozempic have surged for Medicare beneficiaries in ...

The two longer-term headwinds facing GLP-1 drugs — Medicare negotiations going into effect in 2027 and the patent cliff for semaglutide in 2032 — are why the company has already started ...

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to a new study.